BioSpace - Medivation, Inc. News, Search Jobs, Events

BioSpace Login

Enter your BioSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
BioPharm Insight

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

Medivation, Inc.

201 Spear Street
3rd Floor
San Francisco California 94105 U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at http://www.medivation.com/

Key Statistics

Email: info@medivation.com
Ownership:
Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN

Industry
Biopharmaceutical

Collaborations
Pfizer Inc.

Company News

Medivation, Inc. (MDVN) Reports Second Quarter 2010 Financial Results and Provides Corporate Update 8/10/2010 9:03:18 AM More...

Medivation, Inc. (MDVN) Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010 8/2/2010 7:15:48 AM More...

Medivation, Inc. (MDVN) Reports First Quarter 2010 Financial Results and Provides Corporate Update 5/11/2010 8:57:34 AM More...

Medivation, Inc. (MDVN) Announces First Quarter 2010 Financial Results Teleconference and Webcast on May 10, 2010 5/3/2010 10:31:00 AM More...

Medivation, Inc. (MDVN) and Astellas Pharma Inc. Announce Publication in The Lancet of Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4/15/2010 9:20:54 AM More...

Medivation, Inc. (MDVN) to Cut 20% of Jobs to Reduce Costs 3/30/2010 7:19:59 AM More...

Medivation, Inc. (MDVN) (JOBS) Loses $54.8 Million in 2009 3/16/2010 7:14:39 AM More...

Medivation, Inc. (MDVN) Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 3/12/2010 8:27:52 AM More...

Anavex Life Sciences Corp. (AVXL.OB) Comments on Failure of Pfizer Inc. (PFE) and Medivation, Inc. (MDVN)'s Alzheimer's Investigational Drug Dimebon During Phase 3 Clinical Trials 3/4/2010 10:45:02 AM More...

Medivation, Inc. (MDVN) to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease 3/3/2010 8:07:34 AM More...

1